Master of Medical

Biotechnology [BIOC 8730 - GROUP PRESENTATION RUBRIC]

Team Number: _____ Drug Name: ________________________Date: _________________

Team Members:____________________________________________________________

Category Exceptional: 5 points Very Good: 4 points Good: 3 points Fair: 2 points Poor: 1 point
1. Structure of Very well organized Well organized and Somewhat organized Not so organized and Lacks organization.
presentation and provides an provides very good and provides good provides some Does not provide a
and excellent distinct outline, introduction, outline, introduction, outline, introduction, proper outline,
professionalism outline, introduction, middle (content) and middle (content) and middle (content) and introduction and
middle (content) and conclusion at the end. conclusion at the end. conclusion at the end. middle (content).
Your Score: conclusion at the end. Adheres very well to Adheres well to the Adheres fairly to the Does not conclude at
Adheres excellently the group contract group contract and group contract and the end.
__________ to the group contract and serves as a very serves as a good serves fairly as a Does not adhere to
and serves as an good professional professional team professional team the group contract
excellent professional team member. member. member. and does not serve as
team member. a professional team
member

2. Oral Voice projection is Voice projection is Voice projection is Voice projection is Voice projection is
Presentation excellent. very good. good. Communicates fair. Reflects some poor.
Skills Communicates Communicates information and ideas confidence while
information and ideas information and ideas with good confidence communicating Lacks confidence
Your Score: with confidence and with great confidence and clarity. information and and clarity.
excellent clarity. and clarity. ideas.
__________ Excellent in-depth Very good Good engagement Some engagement Not an engaging
engagement with the engagement with the with the audience. with the audience. presenter.
audience. audience.

3. & 4. Content Excellent details of Very good details of Good details of the Fair details of the Lacks details of the
drug along with its the drug and its drug and its targets. drug and its targets. drug and its target.
targets. Thorough targets. Very good Good inclusion of the Somewhat inclusion Incomplete
Your Score: inclusion of the entire inclusion of the entire entire check list of the entire check information of the
check list (enclosed) check list (enclosed) (enclosed) of the list (enclosed) of the check list (enclosed)
__________ of the chosen drug of the chosen drug chosen drug from its chosen drug from its of the drug from its
from its discovery to from its discovery to discovery to market. discovery to market. discovery to market.
market. Excellent market. Very good Good proper citation Largely proper Lacks citation of
proper citation of proper citation of of credible citation of credible credible references.
credible references. credible references. references. references.
5. Engaging Excellent Very good Good engagement Somewhat engaging Lacks engagement
presentation engagement using engagement using using variety of using variety of using variety of
and creative variety of variety of presentation formats presentation formats presentation formats
description of presentation formats presentation formats such as videos, such as videos, such as videos,
drug contents. such as videos, such as videos, graphics/animations. graphics/animations. graphics/animations.
graphics/animations. graphics/animations. Good creative Some creative Lacks creative
Your Score: Excellent creative Very good creative description of the description of the description of the
description of the description of the chosen drug chosen drug chosen drug
__________ chosen drug chosen drug properties. properties. properties.
properties. properties.
6. Respectful Demonstrates the Respectfully Respectfully Respectfully Does not respectfully
discussion topic has been responds accurately responds accurately responds to few responds to the
following mastered by to the most questions. to some questions. questions. questions.
presentation respectfully
(handling of providing accurate
questions) responses to all
questions.
Your Score:
__________

Total Score/30: _____ Feedback:_____________________________________________

 Master of Medical
Biotechnology [BIOC 8730 - GROUP PRESENTATION RUBRIC]

General Guidelines:
1. Your group presentation is worth 30% of your grades. Each team has been
assigned 30 minutes for presentation, with 5 minutes for questions and in class
discussion about their case at the end. Each team member shall have an equal
amount for their presentation.

2. You are required to submit a soft copy of your presentation 24 hours before your
due date of presentation to your course instructor at tranum@uwindsor.ca
including your academic honor code/pledge for maintaining academic integrity.

3. Your presentation must cover all the points of the following check list:
✓ Identification of the potential drug target(s)
o How important is the drug target (activation or inhibition) for the selected drug?
o What is the function of the target? Which disease pathway does the target
regulate?
o Which intermolecular forces are involved in drug interaction while clearly
identifying pharmacophores?

✓ Identification and validation methods of potential drug targets (e.g. affinity

chromatography, DNA microarrays methods).

✓ Sources of drug discovery may include western and traditional medicine sources.
i.e., how was the drug discovered? Screening methods to find a lead compound.
e.g., High throughput screening or HTS, radioligand binding assays etc.

✓ Lead optimization approaches to improve target interaction and pharmacokinetic

i.e., absorption, distribution, metabolism, and excretion (ADME) properties.

✓ In Vitro and In Vivo studies of research data (Toxicity, PK and PD Assay).

Good Lab Practices (GLP) tox screen would include following tests such as:
• Clinicopathologic and toxicokinetic valuations
• Ames reverse-mutation assay
• CHO-HGPRT mammalian cell forward gene mutation assay
• Cytogenetics assay in primary human lymphocytes
• Micronucleus study in rodents and fertility studies.

✓ Clinical Trials (Phase I/II/III) includes trial design and data for each phase
respectively, regulatory affairs and post-marketing surveillance.
~All the Best ~